Clinical Trials
17 trialsNCT00001465 2026-06-05
Study of the Disease Process of Lymphangioleiomyomatosis
National Institutes of Health Clinical Center (CC)
Recruiting
NCT00001975 2026-06-05
Study of Skin Tumors in Tuberous Sclerosis
National Institutes of Health Clinical Center (CC)
Recruiting
NCT05485831 2026-06-03
EpiTALY
Jazz Pharmaceuticals
Active not recruiting
NCT05044819 2026-06-01
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
Jazz Pharmaceuticals
Phase 4 Active not recruiting
NCT05676099 2026-05-29
TSC Biosample Repository and Natural History Database
National Tuberous Sclerosis Association
Recruiting
NCT00001532 2026-05-22
Role of Genetic Factors in the Development of Lung Disease
National Institutes of Health Clinical Center (CC)
Recruiting
NCT02104011 2026-05-19
STBETA
University Hospital, Bordeaux
Phase 2 Completed
NCT07575347 2026-05-08
PERIO-RA-RE
Institutul Clinic Fundeni
Not yet recruiting
NCT05161494 2026-05-07
GAGA
Universiteit Antwerpen
Completed
NCT07561957 2026-05-01
A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) Guidelines
St. James's Hospital, Ireland
Phase NA Recruiting
NCT05864846 2026-04-27
EpiCom
Jazz Pharmaceuticals
Phase 4 Completed
NCT03050268 2026-04-23
SJFAMILY
St. Jude Children's Research Hospital
Recruiting
NCT02890641 2026-04-17
GENEPHY
Fondation Ophtalmologique Adolphe de Rothschild
Recruiting
NCT02962414 2026-04-02
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
Novartis
Phase 3 Active not recruiting
NCT05252585 2026-04-02
A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)
Novartis
Phase 4 Active not recruiting
NCT06392009 2026-04-01
Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II
GRIN Therapeutics, Inc.
Phase 1/2 Active not recruiting
NCT06311474 2026-03-18
RAINBOW
University of California, Los Angeles
Phase NA Completed